STICH3C Cardiac Magnetic Resonance Observational Study
Recruiting now
Conditions studied: Ischemic Left Ventricle Systolic Dysfunction, Multivessel Coronary Artery Disease
In brief
STICOS will test the hypothesis that residual jeopardized myocardium, late gadolinium enhancement, and non-ischemic substrate after revascularization is associated with postoperative adverse cardiovascular events such as heart failure , readmission, or death. This study will look at whether certain heart tissue abnormalities seen on MRI scans can help predict serious health problems after heart procedures like stents or bypass surgery.
Key facts
- Study ID
- NCT07133984
- Run by
- Weill Medical College of Cornell University
- People needed
- 200
- Starts
- 2024-03-01
- Expected to finish
- 2030-01-01
- Last updated by the study team
- 2025-08-21
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Men and women ≥ 18 years old
- LVEF ≤ 40% (quantified by echo, single-photon emission computed tomography [SPECT], or CMR within 2 months of enrollment)
- Prognostically important CAD: either multivessel CAD (triple vessel or double vessel CAD including left anterior descendant artery (LAD), significant coronary stenosis defined as ≥ 70% based on coronary angiography, fractional flow reserve (FFR) ≤ 0.80 or instantaneous wave-free ratio (iFR) ≤ 0.89) or left main disease (+/- other CAD) for which significant stenosis defined as > 50% based on coronary angiography, intravascular ultrasound (IVUS) minimum luminal area [MLA] value ≤ 6.0 mm2 (< 4.5 mm2 Asian descent), or equivalent optical coherence tomography (OCT) measurements.
- Planned CABG or PCI within 3 months
You may not qualify if…
- Concomitant valve disease or other condition (e.g., LV aneurysm) requiring surgical repair or replacement
- Contraindication to CMR (i.e. magnetically activated materials), gadolinium, regadenoson/adenosine/dipyridamole
- Active neoplasm and/or severe end-organ dysfunction with expected life expectancy less than 5 years.
Where it is running
- NewYork-Presbyterian Brooklyn Methodist Hospital — Brooklyn, New York, United States (enrolling)
- New York Presbyterian - Queens — Flushing, New York, United States (enrolling)
- Weill Cornell Medicine/NewYork Presbyterian Hospital — New York, New York, United States (enrolling)
- MU Vienna Austria — Vienna, Austria (enrolling)
- Libin Cardiovascular Institute — Calgary, Alberta, Canada (enrolling)
- Universite Laval Quebec (CRIUCPQ) Canada — Québec, Canada (enrolling)
- Sunnybrook Health Sciences Centre — Toronto, Canada (enrolling)
- Ruijin Hospital Shanghai Jiao Tong University School of Medicine — Shanghai, China (enrolling)
- Dedinje Cardiovascular Institute — Belgrade, Serbia (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.